MPM BioImpact’s Allakos ALLK Stock Holding History

MPM BioImpact’s Portfolio ALLK Stock Details ALLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-344,900	Closed	-$345K	–	45
2024 Q2	$345K	Buy	+344,900	New	+$410K	0.05%	44

Other funds holding ALLK

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MPM BioImpact's ALLK Position: Q3 2024 in Review

MPM BioImpact sold out of Allakos (ALLK) in Q3 2024, closing a stake of 344,900 shares — an estimated $345K sold.

MPM BioImpact first reported a position in ALLK in Q2 2024 and held it in 1 quarter. The position peaked at $345K in Q2 2024. 78 funds tracked by Wall St. Rank hold ALLK as of Q3 2024.

MPM BioImpact reported no remaining Allakos position as of Q3 2024 after selling out during the quarter.
MPM BioImpact sold 344,900 Allakos shares in Q3 2024, an estimated $345K.
MPM BioImpact first reported a position in Allakos in Q2 2024 and held it in 1 quarter.
MPM BioImpact's Allakos position peaked at $345K in Q2 2024.
78 funds tracked by Wall St. Rank held Allakos as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.